Filtered By:
Source: Clinical Cardiology
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 111 results found since Jan 2013.
Postoperative Strokes and Intracranial Bleeds in Patients With Atrial Fibrillation: The FibStroke Study
ConclusionsPerioperative interruption of OAC is common in patients who suffer a postoperative stroke, even in patients with low‐bleeding‐risk procedures. Postoperative intracranial bleeding is frequently preceded by perioperative heparin bridging.
Source: Clinical Cardiology - April 30, 2016 Category: Cardiology Authors: Antti Palomäki, Tuomas Kiviniemi, Juha E.K. Hartikainen, Pirjo Mustonen, Antti Ylitalo, Ilpo Nuotio, Päivi Hartikainen, Jussi Jaakkola, Riho Luite, K.E. Juhani Airaksinen Tags: Clinical Investigations Source Type: research
Special considerations for therapeutic choice of non –vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation
Nonvalvular atrial fibrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin has been used to prevent AF‐associated stroke for more than 50 years, non–vitamin K antagonist oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban recently have been developed to overcome the disadvantages of warfarin. Based on the results of NOAC clinical trials, Savelieva and Camm made recommendations regarding selection of NOACs in patients with nonvalvular AF. Recent accumulating evidence indicates that NOACs work differently in Asian and non‐Asian individuals. In this review, ...
Source: Clinical Cardiology - August 31, 2016 Category: Cardiology Authors: Ken Okumura, Masatsugu Hori, Norio Tanahashi, A. John Camm Tags: Reviews Source Type: research
Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta ‐analysis
The objectives of the meta‐analysis were to investigate different impact on outcomes of pxAF and non‐pxAF, with and without OAC. Two reviewers searched for prospective studies on risk of stroke and systemic embolism (SE) in pxAF and non‐pxAF, with and without OAC. Quality of evidence was assessed according to GRADE approach. Stroke combined with SE was the main outcome. Meta‐regression was performed to evaluate OAC effect on stroke and SE incidence rate. We identified 18 studies. For a total of 239 528 patient‐years of follow‐up. The incidence rate of stroke/SE was 1.6% (95% confidence interval [CI]: 1.3%‐2...
Source: Clinical Cardiology - April 1, 2017 Category: Cardiology Authors: Alessio Lilli, Andrea Di Cori, Valerio Zac à Tags: REVIEWS Source Type: research
Rationale and design of the BAYES (Interatrial Block and Yearly Events) registry
The prevalence of interatrial block (IAB) is high in the elderly, particularly in those with heart disease. Despite this high prevalence—and the association of IAB with the risk of atrial fibrillation (AF), stroke, and cognitive decline—little information exists about the prognosis of older patients with IAB. P‐wave duration and morphology are associated with risk of developing AF, stroke, and cognitive decline in elderly patients with structural heart disease. The aim of the Interatrial Block and Yearly Events (BAYES) registry is to assess the impact of IAB on the risk of AF and stroke during 3 years of follow‐up....
Source: Clinical Cardiology - September 30, 2016 Category: Cardiology Authors: Manuel Mart ínez‐Sellés, Adrian Baranchuk, Roberto Elosua, Antonio Bayés Luna Tags: Trial Designs Source Type: research
Impact of Concomitant Coronary Artery Disease on Atherosclerotic Plaques in the Aortic Arch in Patients With Severe Aortic Stenosis
ConclusionsIn patients with severe AS, concomitant CAD is associated with severe atherosclerotic burden in the aortic arch. This observation suggests that AS patients with concomitant CAD are at a higher risk for stroke, and that careful evaluation of complex arch plaques by TEE is needed for the risk stratification of stroke in these patients.
Source: Clinical Cardiology - April 12, 2013 Category: Cardiology Authors: Suwako Fujita, Kenichi Sugioka, Yoshiki Matsumura, Asahiro Ito, Takeshi Hozumi, Takao Hasegawa, Akihisa Hanatani, Takahiko Naruko, Makiko Ueda, Minoru Yoshiyama Tags: Clinical Investigation Source Type: research
Associations Between Sleep Duration and Prevalence of Cardiovascular Events
ConclusionsThe results of this cross‐sectional analysis suggest that sleep duration may be associated with the prevalence of various CV events.
Source: Clinical Cardiology - September 1, 2013 Category: Cardiology Authors: Saurabh Aggarwal, Rohit Seth Loomba, Rohit Romesh Arora, Janos Molnar Tags: Clinical Investigation Source Type: research
Patterns of Long‐term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI‐38 Coronary Stent Registry
ConclusionsPatients stabilized for a year after ACS and stenting have low rates of ST relative to overall cardiovascular events. The decision to continue DAPT maybe associated with stent type (DES vs bare‐metal stent) and region.
Source: Clinical Cardiology - February 1, 2014 Category: Cardiology Authors: Marc P. Bonaca, Sabina A. Murphy, Debra Miller, Jean‐Paul R. Herrman, Shmuel Gottlieb, Matyas Keltai, Alberto Menozzi, José C. Nicolau, Petr Widimsky, Elliott M. Antman, Stephen D. Wiviott Tags: Clinical Investigation Source Type: research
Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High‐risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (STUDY‐AF)
ConclusionsOutpatient extended ECG screening for asymptomatic AF is feasible, with AF identified in 1 in 20 subjects and sustained AT/AF identified in 1 in 9 subjects, respectively. We also found a high prevalence of asymptomatic AT and frequent supraventricular ectopic complexes, which may be relevant to development of AF or stroke. If confirmed in a larger study, primary screening for AF could have a significant impact on public health.
Source: Clinical Cardiology - April 14, 2015 Category: Cardiology Authors: Mintu P. Turakhia, Aditya J. Ullal, Donald D. Hoang, Claire T. Than, Jared D. Miller, Karen J. Friday, Marco V. Perez, James V. Freeman, Paul J. Wang, Paul A. Heidenreich Tags: Clinical Investigations Source Type: research
Quality of Anticoagulation With Vitamin K Antagonists
ConclusionsPatients who receive VKA to prevent stroke for AF spend less than half the time within therapeutic range.
Source: Clinical Cardiology - May 11, 2015 Category: Cardiology Authors: Vicente Bertomeu‐González, Manuel Anguita, José Moreno‐Arribas, Ángel Cequier, Javier Muñiz, Jesús Castillo‐Castillo, Juan Sanchis, Inmaculada Roldán, Francisco Marin, Vicente Bertomeu‐Martínez, Tags: Clinical Investigations Source Type: research
Effect of Low‐Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta‐Analyses, and Meta‐Regression Analyses of Randomized Trials
ABSTRACT
This analysis investigated the extent of different outcome reductions from low‐density lipoprotein cholesterol (LDL‐C) lowering following ezetimibe/simvastatin treatment and the proportionality of outcome to LDL‐C reductions. The authors searched PubMed between 1997 and mid‐June 2015 (any language) and the Cochrane Library to identify all randomized controlled trials comparing ezetimibe/simvastatin with placebo or less intensive LDL‐C lowering. Risk ratios (RR) and 95% confidence intervals (CIs), standardized to 20 mg/dL LDL‐C reduction, were calculated for 5 primary outcomes (fatal and nonfatal) and...
Source: Clinical Cardiology - August 18, 2015 Category: Cardiology Authors: Costas Thomopoulos, George Skalis, Helena Michalopoulou, Costas Tsioufis, Thomas Makris Tags: Review Source Type: research
Association Between Very Low Levels of High‐Density Lipoprotein Cholesterol and Long‐term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial
ConclusionsMedically managed ACS patients with very low baseline HDL‐C levels have higher risk of long‐term cardiovascular and all‐cause death but similar risks for nonfatal ischemic outcomes vs patients with higher baseline HDL‐C.
Source: Clinical Cardiology - March 31, 2016 Category: Cardiology Authors: Emil Hagström, Matthew T. Roe, Gail Hafley, Megan L. Neely, Mandeep S. Sidhu, Kenneth J. Winters, Dorairaj Prabhakaran, Harvey D. White, Paul W. Armstrong, Keith A.A. Fox, E. Magnus Ohman, William E. Boden, Tags: Clinical Investigations Source Type: research
Design and Rationale of the RE ‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent thrombosis and coronary events. Triple antithrombotic therapy, typically comprising warfarin, aspirin, and clopidogrel, is associated with a high risk of bleeding. A modest‐sized trial of oral anticoagulation with warfarin and clopidogrel without aspirin showed improvements in both bleeding and thrombotic events compared with triple therapy, but large trials are lacking. The RE‐DUAL PCI trial (NCT...
Source: Clinical Cardiology - July 31, 2016 Category: Cardiology Authors: Christopher P. Cannon, Savion Gropper, Deepak L. Bhatt, Stephen G. Ellis, Takeshi Kimura, Gregory Y.H. Lip, Ph. Gabriel Steg, Jurri ën M. Berg, Jenny Manassie, Jörg Kreuzer, Jon Blatchford, Joseph M. Massaro, Martina Brueckmann, Ernesto Ferreiros Ripoll Tags: Trial Designs Source Type: research
Patterns and predictors of lipid ‐lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed‐care population
ConclusionsIn 2014, only 49% of patients with ASCVD and 40% with only DM had evidence for a filled statin prescription. Those with indications of ischemic stroke, PAD, and DM were less likely to receive statins than those with coronary conditions. Other characteristics such as advanced age, female sex, and noncardiac conditions predicted less statin utilization, thereby representing good targets for quality improvement.
Source: Clinical Cardiology - December 26, 2016 Category: Cardiology Authors: Dylan L. Steen, Irfan Khan, Laura Becker, JoAnne M. Foody, Katherine Gorcyca, Robert J. Sanchez, Robert P. Giugliano Tags: CLINICAL INVESTIGATIONS Source Type: research
Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry
ConclusionsFour‐year systemic ischemic risk in patients with PAD and no history of stroke or transient ischemic attack remains high, and was mainly driven by cardiovascular mortality.
Source: Clinical Cardiology - May 18, 2017 Category: Cardiology Authors: J érémie Abtan, Deepak L. Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Christopher M. Reid, Iris Baumgartner, David Wu, Mary E. Hanson, Hakima Hannachi, Puneet K. Singhal, Philippe Gabriel Steg, Gregory Ducrocq, Tags: CLINICAL INVESTIGATIONS Source Type: research
Cost ‐effectiveness analysis of 30‐month vs 12‐month dual antiplatelet therapy with clopidogrel and aspirin after drug‐eluting stents in patients with acute coronary syndrome
Continuation of dual antiplatelet therapy (DAPT) beyond 1 year reduces late stent thrombosis and ischemic events after drug‐eluting stents (DES) but increases risk of bleeding. We hypothesized that extending DAPT from 12 months to 30 months in patients with acute coronary syndrome (ACS) after DES is cost‐effective. A lifelong decision‐analytic model was designed to simulate 2 antiplatelet strategies in event‐free ACS patients who had completed 12‐month DAPT after DES: aspirin monotherapy (75–162 mg daily) and continuation of DAPT (clopidogrel 75 mg daily plus aspirin 75–162 mg daily) for 18 months. Clinical e...
Source: Clinical Cardiology - June 1, 2017 Category: Cardiology Authors: Minghuan Jiang, Joyce H.S. You Tags: QUALITY AND OUTCOMES Source Type: research
